IL17A Blockade with Ixekizumab Suppresses MuvB Signaling in Clinical Psoriasis
Authors:
Open Access
- 24 March 2023
- journal article
- research article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (9) , 1689-1699
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- NIDDK (U24DK097771)
- Eli Lilly and Company (LY2439821)
- NCI (CA125123, CA184427)
This publication has 61 references indexed in Scilit:
- Expanding the Psoriasis Disease Profile: Interrogation of the Skin and Serum of Patients with Moderate-to-Severe PsoriasisJournal of Investigative Dermatology, 2012
- Combined Use of Laser Capture Microdissection and cDNA Microarray Analysis Identifies Locally Expressed Disease-Related Genes in Focal Regions of Psoriasis Vulgaris Skin LesionsJournal of Investigative Dermatology, 2012
- Heterogeneity of Inflammatory and Cytokine Networks in Chronic Plaque PsoriasisPLOS ONE, 2012
- The MuvB complex sequentially recruits B-Myb and FoxM1 to promote mitotic gene expressionGenes & Development, 2012
- Transcriptional Profiling of Psoriasis Using RNA-seq Reveals Previously Unidentified Differentially Expressed GenesJournal of Investigative Dermatology, 2012
- Evaluation of the Psoriasis Transcriptome across Different Studies by Gene Set Enrichment Analysis (GSEA)PLOS ONE, 2010
- Global Gene Expression Analysis Reveals Evidence for Decreased Lipid Biosynthesis and Increased Innate Immunity in Uninvolved Psoriatic SkinJournal of Investigative Dermatology, 2009
- Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genesJournal of Allergy and Clinical Immunology, 2009
- Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathwaysNature Genetics, 2009
- Type I Interferon: Potential Therapeutic Target for Psoriasis?PLOS ONE, 2008